Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma Holding AB will be moved from Nasdaq Stockholm’s Small Cap to the Mid Cap segment following Nasdaq’s annual review of Nordic market capitalization segments, with the reclassification taking effect on January 2, 2026. The move to the Mid Cap segment reflects the company’s increased market value and may enhance its visibility among investors and within the Nordic life sciences sector, potentially supporting broader interest in its clinical pipeline and long-term growth prospects.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a Stockholm-based clinical-stage pharmaceutical company focused on developing a novel class of angiotensin II type 2 receptor agonists (ATRAGs) as disease-modifying treatments for respiratory and fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). Its lead candidate, buloxibutid, is a first-in-class oral small molecule ATRAG that has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and is currently being evaluated in a global 52-week Phase 2b ASPIRE trial in IPF. The company’s shares trade on Nasdaq Stockholm’s main market under the ticker VICO.
Average Trading Volume: 612,557
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.76B
For detailed information about VICO stock, go to TipRanks’ Stock Analysis page.